Bristol-Myers Squibb (BMY) Total Debt (2008 - 2026)
Bristol-Myers Squibb (BMY) total debt from Dec 31, 2008 to Mar 31, 2026. The current Bristol-Myers Squibb (BMY) total debt is $66B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Total Debt
Total Debt
Bristol-Myers Squibb (BMY) Total Debt CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -3.88% |
| 3 Years TTM | +3.94% |
| 5 Years TTM | -1.07% |
| 10 Years TTM | +15.77% |
| All Time TTM | +11.69% |
Annual Total Debt change of Bristol-Myers Squibb (BMY)
| Year | Total Debt | Change |
|---|---|---|
| 2025 | $72B | -6.14% |
| 2024 | $76B | +16.05% |
| 2023 | $66B | -0.04% |
| 2022 | $66B | -10.38% |
| 2021 | $73B | -9.05% |
| 2020 | $81B | N/A |
| 2020 | $0 | N/A |
| 2020 | $0 | N/A |
| 2020 | $0 | -100.00% |
| 2019 | $78B | N/A |
| 2019 | $0 | N/A |
| 2019 | $0 | N/A |
| 2019 | $0 | -100.00% |
| 2018 | $21B | N/A |
| 2018 | $0 | N/A |
| 2018 | $0 | N/A |
| 2018 | $0 | -100.00% |
| 2017 | $22B | N/A |
| 2017 | $0 | N/A |
| 2017 | $0 | N/A |
| 2017 | $0 | -100.00% |
| 2016 | $17B | N/A |
| 2016 | $0 | N/A |
| 2016 | $0 | N/A |
| 2016 | $0 | -100.00% |
| 2015 | $17B | N/A |
| 2015 | $0 | N/A |
| 2015 | $0 | N/A |
| 2015 | $0 | -100.00% |
| 2014 | $19B | N/A |
| 2014 | $0 | N/A |
| 2014 | $0 | N/A |
| 2014 | $0 | -100.00% |
| 2013 | $23B | N/A |
| 2013 | $0 | N/A |
| 2013 | $0 | N/A |
| 2013 | $0 | -100.00% |
| 2012 | $22B | N/A |
| 2012 | $0 | N/A |
| 2012 | $0 | N/A |
| 2012 | $0 | -100.00% |
| 2011 | $17B | N/A |
| 2011 | $0 | N/A |
| 2011 | $0 | N/A |
| 2011 | $0 | -100.00% |
| 2010 | $15B | -4.84% |
| 2009 | $16B | -6.11% |
| 2008 | $17B | N/A |
Comparison Bristol-Myers Squibb (BMY) total debt with competitors
Bristol-Myers Squibb (BMY) total debt is $66.37B.
| Ticker | Name | Total Debt | Upside |
|---|---|---|---|
| MIRA | Mira Pharmaceuticals Inc | $114761.00 | -100.00% |
| NSRX | Nasus Pharma Ltd | $2.24M | -100.00% |
| MDCX | MDCorp | $6.00M | -99.99% |
| MDCXW | Medicus Pharma Ltd warrant | $6.00M | -99.99% |
| AMRN | Amarin Corp | $196.35M | -99.70% |
| SCLX | Scilex Holding Company | $547.71M | -99.17% |
| BIIB | Biogen Inc | $10.83B | -83.68% |
| OGN | Organon & Company | $12.09B | -81.78% |
| GRFS | Grifols SA | $12.24B | -81.55% |
| SNY | Sanofi | $54.88B | -17.32% |
| GSK | GSK Plc | $59.93B | -9.71% |
| AZN | Astrazeneca plc | $66.63B | +0.39% |
| NVS | Novartis AG | $79.61B | +19.93% |
| PFE | Pfizer Inc | $117.21B | +76.60% |
| JNJ | Johnson & Johnson | $119.71B | +80.35% |
| NVO | Novo Nordisk | $356.16B | +436.59% |